Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MRVI 
Maravai Lifesciences Holdings Inc (MRVI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: MRVI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.12
1 Year Target Price $4.12
| 5 | Strong Buy |
| 1 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.44% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 977.34M USD | Price to earnings Ratio - | 1Y Target Price 4.12 |
Price to earnings Ratio - | 1Y Target Price 4.12 | ||
Volume (30-day avg) 13 | Beta 0.29 | 52 Weeks Range 1.67 - 9.50 | Updated Date 09/14/2025 |
52 Weeks Range 1.67 - 9.50 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -87.57% | Operating Margin (TTM) -75.3% |
Management Effectiveness
Return on Assets (TTM) -5.89% | Return on Equity (TTM) -54.84% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 479971653 | Price to Sales(TTM) 4.45 |
Enterprise Value 479971653 | Price to Sales(TTM) 4.45 | ||
Enterprise Value to Revenue 2.18 | Enterprise Value to EBITDA 1.77 | Shares Outstanding 144678000 | Shares Floating 92644412 |
Shares Outstanding 144678000 | Shares Floating 92644412 | ||
Percent Insiders 10.16 | Percent Institutions 90.18 |
Upturn AI SWOT
Maravai Lifesciences Holdings Inc
Company Overview
History and Background
Maravai Lifesciences was founded in 2014 and went public in 2020. It focuses on providing critical products and services to support the development of drugs, vaccines, and diagnostics.
Core Business Areas
- Nucleic Acid Production: Provides high-purity nucleic acids, including mRNA and DNA, used in vaccine and therapeutic development. This segment supports research through commercialization.
- Biologics Safety Testing: Offers services to assess the safety and purity of biologics, including antibody-based therapies and vaccines, ensuring regulatory compliance.
- Protein Detection: Develops and manufactures reagents and assays for protein detection and quantification, crucial for research, diagnostics, and bioprocessing.
Leadership and Structure
The leadership team includes Carl Hull (CEO), Kevin Herde (CFO). The organizational structure includes distinct operational units focused on nucleic acids, biologics safety testing, and protein detection.
Top Products and Market Share
Key Offerings
- CleanCap mRNA capping technology: CleanCap is a key product, providing a superior mRNA capping solution, revenue is embedded in the Nucleic Acid Production segment. Competitors include TriLink BioTechnologies and Aldevron (Danaher).
- Cygnus Technologies: Cygnus Technologies focuses on host cell protein (HCP) detection and quantification. Market share in HCP detection solutions is significant, estimated to be one of the leading providers. Competitors include Meso Scale Discovery, and ELISA kits from various vendors
- Vector Laboratories: Vector Laboratories provides labeling and detection reagents. The company generates revenue through licensing its products. Competitors include Jackson ImmunoResearch, Thermo Fisher Scientific.
Market Dynamics
Industry Overview
The life sciences industry is experiencing rapid growth driven by advancements in genomics, personalized medicine, and biopharmaceutical development. Demand is high for specialized reagents, testing services, and manufacturing solutions.
Positioning
Maravai is positioned as a critical supplier of high-quality reagents and services, enabling the development and production of life-saving therapies and vaccines. Its competitive advantage lies in its specialized technologies and expertise.
Total Addressable Market (TAM)
The total addressable market for Maravai's core offerings is estimated to be billions of dollars. Maravai is well-positioned within this TAM due to its focused expertise in critical areas of biopharmaceutical development and manufacturing.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Strong customer relationships
- High-quality products and services
- Experienced management team
- Proprietary technologies
Weaknesses
- Dependence on the biopharmaceutical industry
- Customer concentration
- Exposure to regulations
- Potential supply chain disruptions
Opportunities
- Expanding into new geographic markets
- Developing new products and services
- Acquiring complementary businesses
- Increased demand for mRNA technologies
Threats
- Intense competition
- Technological obsolescence
- Changes in regulations
- Economic downturns
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Merck KGaA (MRK.DE)
Competitive Landscape
Maravai's competitive advantage lies in its specialized product portfolio and expertise in mRNA and biologics safety testing. However, it faces strong competition from larger, more diversified companies.
Major Acquisitions
Alphazyme LLC
- Year: 2021
- Acquisition Price (USD millions): 175
- Strategic Rationale: Expanded enzymatic capabilities for mRNA synthesis.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends have been strong, driven by demand for mRNA technologies. Recent years have been heavily influenced by the pandemic and subsequent vaccine development.
Future Projections: Future growth is projected to be driven by continued demand for mRNA, biologics safety testing and overall expansion within the biopharmaceutical industry.
Recent Initiatives: Recent initiatives include expanding production capacity, investing in research and development, and pursuing strategic acquisitions.
Summary
Maravai Lifesciences is a key player in providing critical products and services for the biopharmaceutical industry, particularly in mRNA technology. Their focused expertise and high-quality offerings drive growth, though competition from larger, diversified companies is a significant factor. Recent strategic acquisitions strengthen their position. While demand for mRNA therapeutics remains robust, monitoring industry trends and adapting to regulatory changes are essential for sustained success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst reports
- Industry publications
- SEC Filings
- Market Data
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data may be delayed. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Maravai Lifesciences Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-20 | CEO & Director Mr. Bernd Brust | ||
Sector Healthcare | Industry Biotechnology | Full time employees 560 | Website https://www.maravai.com |
Full time employees 560 | Website https://www.maravai.com | ||
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.